Patent ID: 11939389
Assignee: NOVARTIS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 3:
4. The method of claim 3, wherein the second therapeutic agent is:
(a) a PD-1 inhibitor;
(b) a PD-L1 inhibitor;
(c) a LAG-3 inhibitor;
(d) a TIM-3 inhibitor;
(e) a CTLA-4 inhibitor;
(f) an interleukin-15 (IL-15) polypeptide, an interleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination of both an IL-15 polypeptide and an IL-15Ra polypeptide;
(g) an interleukin-12 (IL-12) polypeptide; or
(h) an mTOR inhibitor.